Rapport Therapeutics presents results from Phase 2a trial of RAP-219

Rapport Therapeutics (RAPP) announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures, FOS, in a late-breaker podium presentation at the 2026 American Academy of Neurology, AAN, Annual Meeting, taking place April 18-22, 2026 in Chicago. In the Phase 2a trial, patients received RAP-219 for 8 weeks and then entered an 8-week follow-up period after treatment ended to evaluate the effect of RAP-219 on long episodes and clinical seizures. Therapeutic levels of RAP-219 were sustained, resulting in continued biomarker and clinical responses in the 8-week follow-up period. In the first four weeks of follow-up, RAP-219 showed greater reductions in LEs and clinical seizures than were observed during the 8-week treatment period. Clinically meaningful improvements over baseline continued through the second four weeks of follow-up.